URGN - ユ―ロジェン・ファ―マ （UroGen Pharma Ltd.） ユ―ロジェン・ファ―マURGNのチャート
URGNの企業情報
| symbol | URGN |
|---|---|
| 会社名 | UroGen Pharma Ltd （ユ―ロジェン・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Urogen Pharma Ltd formerly Theracoat Ltd is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy. ユ―ロジェン・ファ―マは、イスラエルのバイオ医薬品企業。泌尿器科疾患向けの新しい治療法の開発に焦点を当て、臨床事業を展開。主要製品候補には、化学療法薬であるミトミシンCの製剤「MitoGel」と「VesiGel」がある。また、表在性尿路上皮癌の治療用として、非外科的手段によって腫瘍を除去するように設計された科学的除去製剤の開発を手掛ける。 Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. |
| 本社所在地 | 9 Ha?Ta?asiya Street Ra?anana 4365007 ISR |
| 代表者氏名 | Arie S. Belldegrun Arie S. Belldegrun |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +972 9-770-7600 |
| 設立年月日 | 38078 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 46人 |
| url | www.urogen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/urgn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -42.16900 |
| 終値（lastsale） | 45.175 |
| 時価総額（marketcap） | 716172195.05 |
| 時価総額 | 時価総額（百万ドル） 662.19180 |
| 売上高 | 売上高（百万ドル） 8.98400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 543.08280 |
| 当期純利益 | 当期純利益（百万ドル） -41.79200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Urogen Pharma Ltd revenues increased from $19K to $845K. Net loss applicable to common stockholders increased from $10.4M to $31.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and Administrative Expenses - Ba increase from $2.3M to $9.3M (expense). |
URGNのテクニカル分析
URGNのニュース
Results of the First Post-Commercial Utilization Review of JELMYTO Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer 2023/01/11 13:00:00 Wallstreet:Online
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest post-commercial utilization review of JELMYTO (mitomycin) for pyelocalyceal solution. This study evaluated 132 patients treated with JELMYTO from 15 high-volume academic and community
UroGen Pharma''s Return On Capital Employed Overview 2022/12/20 14:47:50 Benzinga
According to Benzinga Pro data, during Q3, UroGen Pharma (NASDAQ: URGN ) posted sales of $16.10 million. Earnings were up 3.22%, but UroGen Pharma still reported an overall loss of $25.83 million. In Q2, UroGen Pharma brought in $16.60 million in sales but lost $26.69 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a … Full story available on Benzinga.com
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) 2022/12/19 13:00:00 Investors Urogen
--If approved, UGN-102 would be the first non-surgical primary therapeutic to treat a subset of bladder cancer characterized by high recurrence rates and multiple surgeries PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 19, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer 2022/12/02 00:00:00 Investors Urogen
--Results from this ongoing, non-interventional, rollover study were presented at the 23 rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego SAN DIEGO --(BUSINESS WIRE)--Dec. 1, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer 2022/12/02 00:00:00 Wallstreet:Online
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced new data from the OLYMPUS registration trial designed to obtain long-term follow-up data on JELMYTO (mitomycin) for pyelocalyceal solution that shows median durability of response (DOR) of 28.9 months. The study (Abstract #158) was presented at
UroGen Pharma to Present at Upcoming Investor Conferences 2022/05/18 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences: H.C. Wainwright & Co. Global Investment Conference Wednesday, May 25 at 11:00 a.m. ET Jefferies Healthcare Conference Thursday, June 9 at 1:00 p.m. ET Webcasts of both the H.C. Wainwright & Co. and Jefferies presenta
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer 2022/05/16 18:50:00 Wallstreet:Online
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today highlights new data on real-world experience utilizing the antegrade approach via nephrostomy tube for administration of JELMYTO (mitomycin) for pyelocalyceal solution. This data adds to a growing body of evidence on the safety and efficacy profile of the
Oppenheimer Equities Analysts Raise Earnings Estimates for UroGen Pharma Ltd. (NASDAQ:URGN) 2022/05/16 05:31:13 ForexTV
Stock analysts at Oppenheimer increased their Q2 2022 EPS estimates for UroGen Pharma in a research report issued on Wednesday, May 11th. Oppenheimer analyst L. Gershell now expects that the company … Read Full Story at source (may require registration) The post Oppenheimer Equities Analysts Raise Earnings Estimates for UroGen Pharma Ltd. (NASDAQ:URGN) appeared first on ForexTV .
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript 2022/05/10 20:35:26 Seeking Alpha
UroGen Pharma Ltd. (NASDAQ:NASDAQ:URGN) Q1 2022 Earnings Conference Call May 10, 2022, 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and…
UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M (NASDAQ:URGN) 2022/05/10 13:10:07 Seeking Alpha
UroGen Pharma press release (NASDAQ:URGN): Q1 GAAP EPS of -$1.25 beats by $0.09.Revenue of $13.56M (+81.0% Y/Y) misses by $1.62M.
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022 2022/03/04 20:00:00 Investors Urogen
Conference Call and Webcast Scheduled for Thursday, March 10, 2022 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference 2022/02/28 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time. A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of th
UroGen begins phase 3 trial of UGN-102 to treat bladder cancer 2022/02/03 16:24:48 Seeking Alpha
UroGen Pharma <> began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive
UroGen Pharma Ltd. (NASDAQ:URGN) Expected to Post Quarterly Sales of $17.20 Million 2021/12/22 21:08:42 Dakota Financial News
Wall Street analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN) will announce sales of $17.20 million for the current quarter, Zacks reports. Two analysts have issued estimates for UroGen Pharmas earnings. The lowest sales estimate is $16.50 million and the highest is $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last []
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Bank of America Corp DE 2021/12/12 09:28:42 Dakota Financial News
Bank of America Corp DE grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 169.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,635 shares of the companys stock after buying an additional 56,313 shares during the period. Bank of America []